NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor IndicationsBusiness Wire • 06/05/22
Nanobiotix's (NBTX) CEO Laurent Levy on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/19/22
CORRECTING and REPLACING: NANOBIOTIX Provides First Quarter Operational and Financial UpdateBusiness Wire • 05/19/22
NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022Business Wire • 05/17/22
New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022 ASCO Annual MeetingBusiness Wire • 05/02/22
NANOBOTIX: New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, LAG-3, and TIGIT When Combined With Radiotherapy-Activated NBTXR3Business Wire • 04/11/22
NANOBIOTIX Announces Filing of the 2021 Universal Registration Document and the 2021 Annual Report on Form 20-FBusiness Wire • 04/08/22
Nanobiotix S.A (NBTX) CEO Laurent Levy on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/31/22
NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial ResultsBusiness Wire • 03/30/22
Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic CancerBusiness Wire • 02/09/22
NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4Business Wire • 01/26/22
NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone TargetsBusiness Wire • 01/10/22
NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck CancerBusiness Wire • 01/05/22
Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022Business Wire • 01/04/22
NANOBIOTIX Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkpoint Inhibitor CombinationBusiness Wire • 11/09/21
NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare ConferenceBusiness Wire • 11/03/21
NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC in Phase I Expansion Evaluating Nbtxr3 as a Single Agent Activated by RadiotherapyBusiness Wire • 10/24/21